Allyx Therapeutics is developing an oral drug that demonstrates reversal of learning and memory deficits due to Alzheimer’s disease.
Location: United States, New York
Founded date: 2018
Investors 3
| Date | Name | Website |
| 26.05.2021 | Life Scien... | lifescienc... |
| - | Connecticu... | ctinnovati... |
| 28.10.2021 | Harbor Str... | harborstre... |
Mentions in press and media 3
| Date | Title | Description |
| 18.10.2024 | Allyx Therapeutics: $3.3 Million Grant Awarded From NIH | Allyx Therapeutics announced that it has been awarded a $3.3 million grant from the National Institutes of Health as part of its Small Business Innovation Research Commercial Readiness Pilot program. This funding round will support further ... |
| 15.10.2024 | Allyx Therapeutics Awarded $3.3 Million NIH Grant to Support Further Clinical Studies of Lead Candidate ALX-001 | NEW HAVEN, Conn., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Allyx Therapeutics announced today that it has been awarded a $3.3 million grant from the National Institutes of Health as part of its Small Business Innovation Research Commercial Readine... |
| 13.01.2021 | Allyx Therapeutics Announces License For The Treatment of Cognitive Deficits in Neurodegenerative Disorders From Bristol Myers Squibb And Yale | NEW HAVEN, Conn. (PRWEB) January 13, 2021 Today, Allyx Therapeutics announced the completion of a license agreement with Bristol Myers Squibb to develop Allyx’s novel therapy for Alzheimer’s disease. The agreement includes a sublicense of c... |